Hologic (NASDAQ:HOLX) Price Target Raised to $90.00 at Argus

Key Points

• Argus has raised its price target for Hologic (NADSAQ:HOLX) stock from $80.00 to $90.00, indicating a potential upside of 31.83% based on current prices.
• Hologic reported a quarterly earnings per share of $1.08, surpassing the consensus estimate of $1.05, and achieved a revenue of $1.02 billion, slightly exceeding analyst expectations.
• Institutional investors hold a significant stake in Hologic, with approximately 94.73% of the company's stock owned by these entities, reflecting strong confidence in the firm's prospects.

Hologic (NASDAQ:HOLX - Get Free Report) had its price objective raised by research analysts at Argus from $80.00 to $90.00 in a research note issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the medical equipment provider's stock. Argus' target price points to a potential upside of 35.69% from the company's previous close.

A number of other analysts have also issued reports on HOLX. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, September 15th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. Stephens restated an "overweight" rating and set a $78.00 target price on shares of Hologic in a research report on Thursday. Morgan Stanley boosted their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $79.38.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $1.94 during midday trading on Friday, reaching $66.33. 8,515,121 shares of the company traded hands, compared to its average volume of 1,762,988. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic has a 12 month low of $51.90 and a 12 month high of $84.39. The firm has a market capitalization of $14.75 billion, a price-to-earnings ratio of 27.52, a price-to-earnings-growth ratio of 2.40 and a beta of 0.57. The firm's fifty day moving average price is $66.47 and its two-hundred day moving average price is $62.75.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company posted $1.06 EPS. The firm's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts expect that Hologic will post 4.28 earnings per share for the current year.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. boosted its holdings in Hologic by 22.7% during the 2nd quarter. Osaic Holdings Inc. now owns 20,163 shares of the medical equipment provider's stock valued at $1,310,000 after acquiring an additional 3,736 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in Hologic during the 2nd quarter valued at about $40,000. Headlands Technologies LLC raised its position in Hologic by 2.6% during the 2nd quarter. Headlands Technologies LLC now owns 40,380 shares of the medical equipment provider's stock valued at $2,631,000 after purchasing an additional 1,036 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in Hologic by 23.1% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 351,042 shares of the medical equipment provider's stock valued at $22,903,000 after purchasing an additional 65,848 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Hologic by 40.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,048 shares of the medical equipment provider's stock valued at $264,000 after purchasing an additional 1,157 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.